The current status of the marketing of Mobotinib (Mobosetinib) in China and its therapeutic applications

Mobocertinib (Mobocertinib), as an innovative oral tyrosine kinase inhibitor (TKI), was developed specifically for the treatment of non-small cell lung cancer (NSCLC). This drug mainly acts on the exon 20 insertion mutation of the epidermal growth factor receptor (EGFR), and effectively inhibits the growth and spread of cancer cells by blocking the signal transduction activated by the EGFR mutation.

Currently, Mobotinib (Mobosetinib) has been launched in China, but it has not yet been included in the medical insurance directory, causing patients to face certain difficulties when purchasing it domestically. For specific purchase matters, patients are advised to consult their local hospital pharmacy for detailed information. In the international market, Mobotinib (Mobosetinib) exists in two forms: original drug and generic drug. Original drugs, such as the Hong Kong version of Japan's Takeda Pharmaceutical products, are relatively expensive, about 7,000 to 8,000 yuan. Relatively speaking, generic drugs mainly come from Laos and Bangladesh. The price is more affordable, about more than 3,000 yuan, and the drug ingredients are similar to the original drugs.

Mobotinib is particularly suitable for patients with advanced or metastatic NSCLC who have previously received platinum-containing chemotherapy and have EGFR exon 20 insertion mutations. The emergence of this drug provides a new treatment option for patients with this specific mutation, because traditional EGFR-TKI therapies (such as erlotinib, gefitinib, etc.) are often ineffective for them. In 2021, mobosetinib (mobosetinib) received accelerated approval from the U.S. Food and Drug Administration (FDA) due to its significant therapeutic effect.

However, the use of mobosetinib may also be associated with a range of side effects, including diarrhea, rash, mouth sores, loss of appetite, and nausea. Doctors need to closely monitor the patient's heart function during treatment because the drug may cause heart-related adverse reactions such as QT prolongation. At the same time, abnormal liver function is also a potential risk that needs to be paid attention to when using this drug.

In clinical practice,Mobotinib (mobosetinib) It is usually recommended to be taken once daily, and its absorption is not affected by food. Considering that this drug has many side effects, doctors will flexibly adjust the dosage according to the patient's tolerance and disease progression. In addition, since mobosetinib is mainly metabolized by theCYP3A4enzyme system, special attention must be paid to drug-drug interactions when using the drug, and avoid simultaneous use with strong inhibitors or strong inducers of CYP3A4 to ensure patient medication safety.